Troglitazone

Troglitazone
Clinical data
Trade namesRezulin, Resulin, Romozin, Noscal
Routes of
administration		By mouth (tablets)
ATC code
Legal status
Legal status
  • Production and promotion ceased
Pharmacokinetic data
Elimination half-life16–34 hours
Identifiers
  • (RS)-5-(4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl)thiazolidine-2,4-dione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H27NO5S
Molar mass441.54 g·mol−1
3D model (JSmol)
Melting point184 to 186 °C (363 to 367 °F)
  • O=C1NC(=O)SC1Cc4ccc(OCC3(Oc2c(c(c(O)c(c2CC3)C)C)C)C)cc4
  • InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28) checkY
  • Key:GXPHKUHSUJUWKP-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Troglitazone is an antidiabetic and anti-inflammatory drug, and a member of the drug class of the thiazolidinediones. It was prescribed for people with diabetes mellitus type 2.[1]

It was patented in 1983 and approved for medical use in 1997.[2] It was subsequently withdrawn.

  1. ^ Fisher L (4 November 1997). "Adverse Diabetes Drug News Sends Warner-Lambert Down". The New York Times. Retrieved 12 December 2012.
  2. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 450. ISBN 9783527607495.